Comparative Pharmacology
Head-to-head clinical analysis: FABRAZYME versus VPRIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FABRAZYME versus VPRIV.
FABRAZYME vs VPRIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fabrazyme (agalsidase beta) is a recombinant human alpha-galactosidase A enzyme that hydrolyzes globotriaosylceramide (Gb3) and other glycosphingolipids with terminal alpha-galactosyl residues, thereby reducing accumulation of these substrates in tissues.
VPRIV (velaglucerase alfa) is a recombinant form of human lysosomal glucocerebrosidase that hydrolyzes glucocerebroside to glucose and ceramide, replacing the deficient enzyme in Gaucher disease.
1 mg/kg intravenously every 2 weeks infused over 4-6 hours.
60 U/kg intravenously every 2 weeks over 4 hours.
None Documented
None Documented
Terminal elimination half-life ranges from 80 to 120 minutes (1.3-2 hours) in adults, which supports a bi-weekly intravenous dosing regimen.
Terminal elimination half-life is approximately 30 minutes (range 15-60 minutes) in Gaucher disease patients, necessitating intravenous infusion over 1-2 hours every other week.
Primarily eliminated via renal pathways; 55-65% of the administered dose is recovered in urine as unchanged drug, with less than 5% recovered in feces.
Primarily metabolized via peptide hydrolysis; elimination is predominantly non-renal. Renal excretion accounts for <5% of the dose as intact drug. Fecal elimination of metabolites is negligible.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy